Form 4: Nuvalent CFO Alexandra Balcom Executes Stock Option and Sells Shares Under 10b5-1 Plan

Nuvalent's CFO, Alexandra Balcom, exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 30, 2024, Alexandra Balcom, the Chief Financial Officer of Nuvalent, Inc., executed a transaction involving the company's stock.
• Balcom exercised a stock option to acquire 10,000 shares of Class A Common Stock at a price of $27.85 per share.
• Concurrently, Balcom sold 5,231 shares at an average price of $83.87, 4,481 shares at an average price of $84.55, and 288 shares at an average price of $85.96.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 28, 2023.
• Following these transactions, Balcom directly owns 33,300 shares of Class A Common Stock and 114,200 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment as the filing simply reports transactions under a pre-existing plan. The CFO is selling shares, which could be seen as slightly negative, but the 10b5-1 plan mitigates this concern.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating transparency and avoiding concerns about insider trading based on non-public information.

Risks

• While the 10b5-1 plan mitigates concerns, large sales by insiders can sometimes be perceived negatively by the market.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Insider transactions are common and closely watched in the biotech industry. The use of a 10b5-1 plan is a standard practice to ensure compliance with insider trading regulations.

Comparison to Industry Standards

• Similar transactions are routinely disclosed by executives at comparable biotech firms such as Relay Therapeutics, Black Diamond Therapeutics, and Blueprint Medicines.
• The use of 10b5-1 trading plans is a common practice among executives in publicly traded companies to manage their stock holdings while avoiding accusations of insider trading.
• The reported weighted average sale prices are within the typical range observed for similar transactions in the biotech sector.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by a key executive, but the existence of the 10b5-1 plan should reassure investors.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates